[Effectiveness of levofloxacin (Tavanik, "Aventis Pharma") in the treatment of complicated infections of the urogenital organs].
Derevianko
I I
II
Lavrinova
L N
LN
Kudriashova
E E
EE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D003556:Cystitis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D011472:Prostatitis / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy*; D013997:Time Factors; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D064704:Levofloxacin; D015242:Ofloxacin